A growing number of scientists are looking to stem cells to help identify new targets and design new therapies for ALS. Take a look back at their key advances in this interactive timeline.

An upcoming US trial aims to determine whether the diaphragm pacer helps people with ALS breathe better and live longer.

A new technique may help researchers identify new immunomodulatory medicines for ALS.

GSK's ozanezumab aims to keep people with ALS moving by helping muscles and motor nerves stay connected.

An upcoming clinical trial asks whether the FDA-approved heart medicine mexiletine might slow ALS by reducing hyperexcitability, a potential early step in the disease.

Biogen Idec's Doug Kerr MD PhD talks dexpramipexole - the lessons learned and the development of future ALS medicines going forward.

Take a look back at ALS in 2012 in this interactive timeline.

Emerging ALS medicines show promise. But key challenges remain to bring them forward to the ALS clinic according to new studies unveiled at ALS MND Chicago.